Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1976 1
1978 1
1980 2
1982 4
1983 6
1984 4
1985 5
1986 3
1987 5
1988 4
1989 5
1990 7
1991 4
1992 6
1993 8
1994 9
1995 13
1996 19
1997 12
1998 13
1999 5
2000 12
2001 6
2002 5
2003 7
2004 7
2005 5
2006 7
2007 4
2008 5
2009 5
2010 2
2011 4
2012 9
2013 3
2014 2
2015 4
2016 2
2018 2
2019 1
2020 1
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trial.
Balik M, Maly M, Brozek T, Rulisek J, Porizka M, Sachl R, Otahal M, Brestovansky P, Svobodova E, Flaksa M, Stach Z, Horejsek J, Volny L, Jurisinova I, Novotny A, Trachta P, Kunstyr J, Kopecky P, Tencer T, Pazout J, Belohlavek J, Duska F, Krajcova A, Waldauf P. Balik M, et al. Intensive Care Med. 2023 Nov;49(11):1283-1292. doi: 10.1007/s00134-023-07208-3. Epub 2023 Sep 12. Intensive Care Med. 2023. PMID: 37698594 Clinical Trial.
After 24 h, 77 (72.8%) and 71 (67.3%) were in sinus rhythm (p = 0.4), restored after a median of 3.7 h (95% CI 2.3-6.8) and 7.3 h (95% CI 5-11), p = 0.02, with propafenone and amiodarone, respectively. The arrhythmia recurred in 54 (52%) patients treated with propafenon …
After 24 h, 77 (72.8%) and 71 (67.3%) were in sinus rhythm (p = 0.4), restored after a median of 3.7 h (95% CI 2.3-6.8) and 7.3 h (95% CI 5- …
[Propafenone and flecainide in the therapy of ventricular arrhythmias].
Paperini L, Davini A, Lattanzi F, Topi A, Reisenhofer B, Squarcini G, Paci A, Topi PL. Paperini L, et al. Minerva Cardioangiol. 1995 Oct;43(10):449-57. Minerva Cardioangiol. 1995. PMID: 8819814 Review. Italian.
Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias. ...Patients of group A were randomly assigned to antiarrhythmic treatment (flecainide 150-300 mg/die or propafenone 450-900 mg/die). …
Flecainide and propafenone are antiarrhythmic drugs of the class 1C (Vaughan and Williams) commonly used for ventricular arrhythmias. …
Propafenone shows class Ic and class II antiarrhythmic effects.
Stoschitzky K, Stoschitzky G, Lercher P, Brussee H, Lamprecht G, Lindner W. Stoschitzky K, et al. Europace. 2016 Apr;18(4):568-71. doi: 10.1093/europace/euv195. Epub 2015 Jun 7. Europace. 2016. PMID: 26056191 Clinical Trial.

Plasma concentrations of propafenone increased during exercise (+23%, P < 0.05) and decreased during recovery (-33%, P < 0.05). ...Therefore, we conclude that propafenone is both a Class Ic and a Class II antiarrhythmic agent, and 600 mg propafenone, i.

…

Plasma concentrations of propafenone increased during exercise (+23%, P < 0.05) and decreased during recovery (-33%, P < 0.05).

…
A Mechanistic Clinical Trial Using (R)- Versus (S)-Propafenone to Test RyR2 (Ryanodine Receptor) Inhibition for the Prevention of Atrial Fibrillation Induction.
Shoemaker MB, Yoneda ZT, Crawford DM, Akers WS, Richardson T, Montgomery JA, Phillips S, Shyr Y, Saavedra P, Estrada JC, Kanagasundram A, Shen ST, Michaud GF, Crossley G, Ellis CR, Knollmann BC. Shoemaker MB, et al. Circ Arrhythm Electrophysiol. 2022 Oct;15(10):e010713. doi: 10.1161/CIRCEP.121.010713. Epub 2022 Sep 27. Circ Arrhythm Electrophysiol. 2022. PMID: 36166682 Free PMC article. Clinical Trial.
Atrial flutter occurred significantly more often in the (R)-propafenone (N=23, 32.4%) and (S)-propafenone (N=26, 34.7%) groups compared to placebo (N=1, 5.3%, P=0.029). ...CONCLUSIONS: There is no difference in AF inducibility between (R)-propafenone and (S)- …
Atrial flutter occurred significantly more often in the (R)-propafenone (N=23, 32.4%) and (S)-propafenone (N=26, 34.7%) groups …
Propafenone quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry in a bioequivalence study.
Severino B, Luisi G, Donomae Iwamoto R, Moreno RA, Perez Teixeira V, Di Vaio P, Saccone I, Magli E, Santagada V, Caliendo G, Mendes GD, De Nucci G. Severino B, et al. Int J Clin Pharmacol Ther. 2018 Jun;56(6):280-291. doi: 10.5414/CP203181. Int J Clin Pharmacol Ther. 2018. PMID: 29648531 Clinical Trial.
Propafenone is an antiarrhythmic drug applied to ventricular arrhythmias, initially recognized as a sodium channel blocker. This study aims to evaluate the bioequivalence of two propafenone formulations (300 mg tablet) in healthy subjects under non-fasting condition …
Propafenone is an antiarrhythmic drug applied to ventricular arrhythmias, initially recognized as a sodium channel blocker. This stud …
Clinical pharmacology of propafenone.
Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. Connolly SJ, et al. Circulation. 1983 Sep;68(3):589-96. doi: 10.1161/01.cir.68.3.589. Circulation. 1983. PMID: 6872170 Clinical Trial.
A nonlinear relationship was found between propafenone dose and steady-state mean concentration with a 10-fold increase in drug concentration as dose increased threefold from 300 to 900 mg/day. There was great intersubject variability in elimination half-life (mean 6 hr, r …
A nonlinear relationship was found between propafenone dose and steady-state mean concentration with a 10-fold increase in drug conce …
Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.
Mörike K, Kivistö KT, Schaeffeler E, Jägle C, Igel S, Drescher S, Fux R, Marx C, Hofmann U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm JO, Gleiter CH, Ziemer G, Rein JG, Hellberg KD, Eichelbaum M, Schwab M. Mörike K, et al. Clin Pharmacol Ther. 2008 Jul;84(1):104-10. doi: 10.1038/sj.clpt.6100473. Epub 2008 Jan 2. Clin Pharmacol Ther. 2008. PMID: 18167502 Clinical Trial.
We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships between CYP2D6 polymorphism and the efficacy, pharmacokinetics, and tolerability of propafenone. ...Plasma propafenone concentra …
We studied the efficacy of propafenone in preventing atrial tachyarrhythmias after cardiac surgery, and the possible relationships be …
Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study.
Faber TS, Zehender M, Krahnefeld O, Daisenberger K, Meinertz T, Just H. Faber TS, et al. J Am Coll Cardiol. 1997 Mar 1;29(3):561-7. doi: 10.1016/s0735-1097(96)00555-4. J Am Coll Cardiol. 1997. PMID: 9060894 Free article. Clinical Trial.
The power of the study to detect clinically meaningful differences in QT dispersion was 0.75, and a twofold increase in QT dispersion in the propafenone group compared with the placebo group was considered clinically relevant. ...These observations may demonstrate a clinic …
The power of the study to detect clinically meaningful differences in QT dispersion was 0.75, and a twofold increase in QT dispersion in the …
Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.
Reimold SC, Cantillon CO, Friedman PL, Antman EM. Reimold SC, et al. Am J Cardiol. 1993 Mar 1;71(7):558-63. doi: 10.1016/0002-9149(93)90511-a. Am J Cardiol. 1993. PMID: 8438741 Clinical Trial.
Except for constipation that occurred more frequently in patients treated with propafenone, adverse side effects were equally distributed between the 2 therapies. Two patients receiving sotalol died during follow-up. Propafenone and sotalol, 2 new antiarrhythmic age …
Except for constipation that occurred more frequently in patients treated with propafenone, adverse side effects were equally distrib …
Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration.
Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Boriani G, et al. Chest. 1995 Aug;108(2):355-8. doi: 10.1378/chest.108.2.355. Chest. 1995. PMID: 7634866 Clinical Trial.
The patients were assigned randomly to treatment with intravenous propafenone (29 patients), oral propafenone (29 patients), or placebo (29 patients). ...RESULTS: Conversion to sinus rhythm was obtained within 1 h in 28% with intravenous propafenone, in 3% wi …
The patients were assigned randomly to treatment with intravenous propafenone (29 patients), oral propafenone (29 patients), o …
233 results

Searches related to "propafenone"